Puma Biotechnology (PBYI) Depreciation & Amortization (CF) (2011 - 2026)

Puma Biotechnology has reported Depreciation & Amortization (CF) for 16 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 7.58% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $10.7 million (down 6.1% YoY), and the FY2025 full-year result was $10.9 million, down 5.09% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.6 million, down from $2.7 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $2.9 million in Q2 2024, with the low at $2.5 million in Q4 2022.
• Historically, Depreciation & Amortization (CF) has averaged $2.7 million across 5 years, with a median of $2.8 million in 2025.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) dropped 17.63% — and 2023, when it rose 17.77%.
• Puma Biotechnology's Depreciation & Amortization (CF) stood at $2.5 million in 2022, then climbed by 17.77% to $2.9 million in 2023, then slipped by 1.66% to $2.8 million in 2024, then decreased by 6.48% to $2.7 million in 2025, then retreated by 2.75% to $2.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.6 million (Q1 2026), $2.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.